Cancer Research UK on Google+ Cancer Research UK on Facebook Cancer Research UK on Twitter
 

Uterine cancer survival statistics

One-, five- and ten-year survival statistics for uterine cancer by age and trends over time are presented here. There are also data by geography and by socio-economic variation. The ICD codes for uterine cancer are ICD-10 C54-C55.

The statistics on these pages give an overall picture of survival. Unless otherwise stated, the statistics include all female adults diagnosed with uterine cancer, at all ages, stages and co-morbidities. The survival time experienced by an individual patient may be much higher or lower, depending on specific patient and tumour characteristics. If you are a patient, you will probably find our CancerHelp pages more relevant and useful.

The latest survival statistics available for uterine cancer in England are 2005-2009 (followed up to 2010). Find out why these are the latest statistics available.

 

One-, five- and ten-year survival

The latest age-standardised relative survival rates for uterine cancer in England during 2005-2009 show that 90.1% of women are expected to survive their disease for at least one year, falling to 77.3% surviving five years or more (Table 3.1).1,2 Broadly similar rates have been reported for Wales, Scotland and Northern Ireland.3-5

Table 3.1: Uterine Cancer (C54-C55), Age-Standardised One-, Five- and Ten-Year Relative Survival Rates, Females (Aged 15-99), England 2005-2009 and England and Wales 2007

Relative Survival (%)
1 Year 5 Year 10 Year
Sex 2005-2009 2005-2009 2007*
Female 90.1 77.3 74.5

Download this table XLS (38KB)

Ten-year survival rate has been predicted for patients diagnosed in 2007 (using the hybrid approach)

A common misconception is to treat five-year survival rates as ‘cure’ rates. However, for uterine cancer, survival continues to fall beyond five years after diagnosis (Table 3.1).1,2  

The five-year relative survival rates for uterine cancer are among the highest of the 21 most common cancers in England.1 These high survival rates are due in large part to that fact that approximately 75% of all patients with endometrial cancer present with early stage disease confined to the body of the uterus.6 Like most cancers, when caught at an early stage treatment is much more effective.

section reviewed 22/06/12
section updated 22/06/12

 

By age

As with nearly all cancers, relative survival for uterine cancer is higher in younger women, even after taking account of the higher background mortality in older people. The reasons for this are likely to include a combination of better general health, more effective response to treatment and earlier diagnosis in younger people overall. Differences in underlying tumour biology may also play a part for some cancer sites.

The five-year relative survival rates for uterine cancer in England during 2005-2009 ranged from 87% in 15-39 year olds to 55% in 80-99 year olds (Figure 3.1).1

Figure 3.1: Uterine Cancer (C54-C55), Five-Year Relative Survival Rates by Age, England 2005-2009

surv_5yr_age_uterus.swf

Download this chart XLS (53KB)

section reviewed 22/06/12
section updated 22/06/12

 

Trends over time

As with the majority of cancers, relative survival for uterine cancer is improving. This can generally be attributed to faster diagnosis and improvements in treatment. However, there is still scope for improvement and increasing cancer survival rates remains a major priority of Improving Outcomes: A Strategy for Cancer.17 An outcome of this Strategy is the National Awareness and Early Diagnosis Initiative (NAEDI), which is a public sector/third sector partnership between the Department of Health, National Cancer Action Team, and Cancer Research UK. The role of NAEDI is to promote the earlier diagnosis of cancer, and this will involve researching ways to further improve survival rates from uterine cancer.  

One-year relative survival rates have been used as an indicator of early diagnosis, since death before one year may be due to the disease being diagnosed at a late stage. One-year relative survival rates for uterine cancer increased from 78% in England and Wales during 1971-1975 to 90.1% in England during 2005-2009 (Figure 3.2).1,7-9  

Figure 3.2: Uterine Cancer (C54-C55), Age-Standardised One-Year Relative Survival Rates, England and Wales 1971-1999, England 2003-2009

surv_1yr_uterus.swf

Download this chart XLS (56KB)

Survival rates are for England only for 2003 onwards

While relative survival rates are still influenced by early diagnosis after five years, they are also strongly dependent on the success of treatment. Five-year relative survival rates for uterine cancer increased from 61% in England and Wales during 1971-1975 to 77.3% in England during 2005-2009 (Figure 3.3).1,7,8,10

Figure 3.3: Uterine Cancer (C54-C55), Age-Standardised Five-Year Relative Survival Rates, England and Wales 1971-1999, England 2001-2009

surv_5yr_uterus.swf

Download this chart XLS (56KB)

Survival rates are for England only from 2001 onwards

Ten-year relative survival rates for women diagnosed with uterine cancer increased from 63% in England and Wales during 1971-1975 to a predicted 74.5% in England in 2007 (Figure 3.4).2,7,11

Figure 3.4: Uterine Cancer (C54-C55), Age-Standardised Ten-Year Relative Survival Rates, England and Wales 1971-1995, and predicted 2007

surv_10yr_uterus.swf

Download this chart XLS (54KB)

Survival rates are not age-standardised from 1971-1985
Ten-year survival rates have been predicted for patients diagnosed in 2007 (using the hybrid approach)

section reviewed 22/06/12
section updated 22/06/12

 

In Europe and worldwide

One-year survival rates for women in England diagnosed with uterine cancer (C54 only) in 1995-99 were significantly below the European average (88%).12 Five-year relative survival was also lower (75%) but not significantly lower than the European average. Women in the United States diagnosed with uterine cancer (C54 only) in 1995-2001 had five-year survival of 85%.13

In the United States there are significant differences in survival between African American and white women.13 While this could partly be due to differences in treatment between the two groups, African American women are significantly more likely to get high-grade tumours and to present at a later stage.14

section reviewed 22/06/12
section updated 22/06/12

 

By socio-economic variation

For women diagnosed in 1996-1999 there is a significant gap in five-year survival between the most deprived and least deprived women of 4.5%.15 Regional differences in survival rates reflect this deprivation gradient. Wales had the lowest relative one and five-year survival rates for women diagnosed in 1986-90, while the South and West regions in England had the highest rates.7

section reviewed 22/06/12
section updated 22/06/12

 

By stage

Five-year survival is around 85% for stage I tumours, compared with 25% for women diagnosed with stage IV.16 Grade also has a bearing on prognosis, with around 81% five-year survival in patients with grade 1 stage Ic tumours compared with 42% for grade 3 tumours of the same stage, although the effect of grade is less marked with tumours diagnosed at stage Ib or Ia.16

section reviewed 22/06/12
section updated 22/06/12

No Error

Rate this page:
Submit rating
Rated 5 out of 5 based on 1 votes
Rate this page
Rate this page for no comments box
Please enter feedback to continue submitting
Send feedback
Question about cancer? Contact our information nurse team

Visit our A-Z topic pages

 

References for uterine (womb) cancer survival

  1. For data for 2005-2009: Office for National Statistics (ONS). Cancer survival in England: Patients diagnosed 2005-2009 and followed up to 2010. London: ONS; 2011.
  2. For data for 2007: Coleman MP, et al. Research commissioned by Cancer Research UK, London School of Hygiene and Tropical Medicine. 2010.
  3. Welsh Cancer Intelligence and Surveillance Unit (WCISU). Cancer Survival Trends in Wales 1985-2004. Cardiff: WCISU; 2010.
  4. Information Services Division Scotland (ISD Scotland). Cancer Statistics. Female genital organs. Accessed September 2011.
  5. Northern Ireland Cancer Registry (NICR). Cancer Survival Online Statistics. Corpus Uteri. Accessed September 2011.
  6. Gien, Kwon J, Oliver TK, et al. Adjuvant hormonal therapy for stage I endometrial cancer. Curr Oncol 2008;15(3):126–135.
  7. For data for 1971-1990: Coleman MP, Babb P, Damiecki P, et al. Cancer Survival Trends in England and Wales, 1971-1995: Deprivation and NHS Region. Series SMPS No 61. London: ONS; 1999.
  8. For data for 1991-1999: Office for National Statistics (ONS). Cancer Survival: England and Wales, 1991-2001, twenty major cancers by age group. London: ONS; 2005.
  9. For data for 2003-2007: Office for National Statistics (ONS). Cancer survival rates, Cancer survival in England, patients diagnosed 2003-2007, followed up to 2008. London: ONS, 2010.
  10. For data for 2001-2006: Office for National Statistics (ONS). Cancer survival rates, Survival Rates in England, patients diagnosed 2001-2006 followed up to 2007. London; ONS, 2009.
  11. For data for 1996-2003: Rachet B, Maringe C, Nur U, et al. Population-based cancer survival trends in England and Wales up to 2007. Lancet Oncol 2009;10:351-369. Age-standardised figures were provided by the author on request.
  12. Sant M, Allemani C, Santaquilani M, et al. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009;45:931-91.
  13. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2003. 5-year survival rates. Maryland, US: National Cancer Institute; 2005.
  14. Hicks ML, Phillips JL, Parham G, et al. The National Cancer Data Base report on endometrial carcinoma in African-American women. Cancer 1998;83(12):2629-37.
  15. Coleman MP, Rachet B, Woods LM, et al. Trends in socioeconomic inequalities in cancer survival in England and Wales up to 2001. BJC 2004;90(7):1367-73
  16. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet 2005;366(9484):491-505.
  17. Department of Health. Improving outcomes: a strategy for cancer. London: Department of Health; 2011.
Updated: 3 September 2012